ClinicalTrials.gg
CompletedNCT04707196Updated Nov 24, 2023Results posted

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

A Phase 4 interventional study of Abemaciclib and Nonsteroidal Aromatase Inhibitor (NSAI) in Breast Neoplasms and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 15 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
16th of 55
200 · median 120
Started
2021
with 6 others
Phase 4
8 of 55
4 open now
Registered
32nd of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 7 that started in 2021, is one of 8 in phase 4, and was the 32nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with hormone therapy in Indian women with advanced breast cancer. Participants must have hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer and must live in India. For each participant, the study could last up to eight months and may include up to eight visits to the study center.

03

Conditions studied

  • Breast Neoplasms
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (-) breast cancer
  • Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or disease
  • Have status
  • Have a performance status of 0 or 1 on the (ECOG) scale
  • Have adequate organ function
  • Have discontinued previous cytotoxic therapies, biological agents, agents, and radiotherapy
  • Are able to swallow oral formulation

Exclusion criteria

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or .
  • Have clinical evidence or history of central nervous system .
  • Have received prior treatment with chemotherapy (except for /adjuvant chemotherapy), fulvestrant, everolimus, or any cyclin-dependent kinase (CDK) 4 \& 6 inhibitor.
  • Have received recent (within 28 days prior to study intervention) (for example, yellow fever). Seasonal flu vaccinations that do not contain a live virus are permitted.
  • Have a personal history of presyncope or syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
  • Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.
  • Have received an or allogeneic stem-cell transplant
  • Have active bacterial or fungal infection, or detectable viral infection (for example, or viral hepatitis). Screening is not required for enrolment.
  • Are pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Abemaciclib + NSAI or Fulvestrant

    Participants received abemaciclib 150 milligram (mg) orally twice daily, on days 1 through 28 of a 28-day cycle, for up to 6 cycles or less in case of disease progression, or any other discontinuation criterion is met, plus either NSAI (nonsteroidal aromatase inhibitors - anastrozole or letrozole) administered orally as per standard of care or fulvestrant administered intramuscularly as per standard of care.

    Drug: Abemaciclib · Drug: Nonsteroidal Aromatase Inhibitor (NSAI) · Drug: Fulvestrant

Interventions

  • Administered orally

    Also known as: LY2835219

  • DrugNonsteroidal Aromatase Inhibitor (NSAI)

    Letrozole or anastrozole administered orally (physician choice)

  • Administered intramuscularly

This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event

    Treatment-emergent adverse events (TEAEs) are defined as any adverse events that started at the time of, or after the, first study medication administration as well as those events that started prior to the first study drug administration, but which worsened after the first study medication administration. The reported data reflects the unique percentage of participants who experienced any serious and other non-serious adverse events. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline until end of follow-up (Up To 7 Months)

Secondary outcomes

  1. Percentage of Participants Who Discontinued From Study Treatment Due to Adverse Events

    An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Baseline until end of study treatment (Up To 6 Months)

07

Results

Posted Nov 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib + NSAIAbemaciclib + Fulvestrant
Started13763
Received at least 1 dose of study drug13763
Completed10843
Not completed2920
Withdrew: Withdrawal by subject96
Withdrew: Lost to follow-up10
Withdrew: Protocol violation41
Withdrew: Adverse event22
Withdrew: Death31
Withdrew: Non-compliance with study drug10
Withdrew: Progressive disease910

Outcome measures

PrimaryPercentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event

Treatment-emergent adverse events (TEAEs) are defined as any adverse events that started at the time of, or after the, first study medication administration as well as those events that started prior to the first study drug administration, but which worsened after the first study medication administration. The reported data reflects the unique percentage of participants who experienced any serious and other non-serious adverse events. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline until end of follow-up (Up To 7 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event
percentage of participantsAbemaciclib + NSAIAbemaciclib + Fulvestrant
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event78.169.8
SecondaryPercentage of Participants Who Discontinued From Study Treatment Due to Adverse Events

An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Baseline until end of study treatment (Up To 6 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From Study Treatment Due to Adverse Events
percentage of participantsAbemaciclib + NSAIAbemaciclib + Fulvestrant
Percentage of Participants Who Discontinued From Study Treatment Due to Adverse Events3.64.8

Adverse events

Collected over Baseline until end of follow-up (Up To 7 Months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + NSAI3/137 (2.2%)9/137 (6.6%)105/137 (76.6%)
Abemaciclib + Fulvestrant1/63 (1.6%)5/63 (7.9%)44/63 (69.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAbemaciclib + NSAIAbemaciclib + Fulvestrant
ThrombocytopeniaBlood and lymphatic system disorders0/1371/63
Cardiac failure congestiveCardiac disorders0/1371/63
Multiple organ dysfunction syndromeGeneral disorders0/1371/63
Covid-19 pneumoniaInfections and infestations0/1371/63
Neutropenic sepsisInfections and infestations0/1371/63
Urinary tract infection pseudomonalInfections and infestations0/1371/63
Pathological fractureMusculoskeletal and connective tissue disorders0/1371/63
PancytopeniaBlood and lymphatic system disorders1/1370/63
Cardio-respiratory arrestCardiac disorders1/1370/63
DiarrhoeaGastrointestinal disorders1/1370/63
Most frequent other events
Showing 10 of 108
Most frequent other events
EventAbemaciclib + NSAIAbemaciclib + Fulvestrant
DiarrhoeaGastrointestinal disorders41/13718/63
NeutropeniaBlood and lymphatic system disorders34/13711/63
AnaemiaBlood and lymphatic system disorders32/13714/63
VomitingGastrointestinal disorders17/13713/63
FatigueGeneral disorders8/13713/63
NauseaGastrointestinal disorders14/13710/63
Neutrophil count decreasedInvestigations6/1379/63
LeukopeniaBlood and lymphatic system disorders19/1376/63
CoughRespiratory, thoracic and mediastinal disorders9/1378/63
White blood cell count decreasedInvestigations6/1377/63

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Abemaciclib + NSAIAbemaciclib + FulvestrantTotal
Mean55.60 ± 11.6651.80 ± 12.5454.40 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + NSAIAbemaciclib + FulvestrantTotal
Female13763200
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + NSAIAbemaciclib + FulvestrantTotal
American Indian or Alaska Native000
Asian13763200
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + NSAIAbemaciclib + FulvestrantTotal
India13763200
08

Study locations

15 sites
  • MNJ Institute of Oncology
    Hyderabad, Andhra Pradesh 500004, India
  • Indira Gandhi Institute of Medical Sciences
    Patna, Bihar 800014, India
  • Rajiv Gandhi Cancer Institute And Research Centre
    New Delhi, Delhi 110085, India
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • Unique Hospital Multispecialty & Research Institute
    Surat, Gujarat 395002, India
  • Kailash Cancer Hospital & Research Centre (KCHRC)
    Waghodia, Gujarat 391760, India
  • HCG Cancer Centre, Kalinga Rao Road
    Bengaluru, Karnataka 560020, India
  • Regional Cancer Centre
    Trivandrum, Kerala 695011, India
  • SRJ-CBCC Cancer Hospital
    Indore, Madhya Pradesh 452001, India
  • Kingsway Hospital
    Nagpur, Maharashtra 440001, India
  • Meditrina Institute of Medical Sciences
    Nagpur, Maharashtra 440012, India
  • HCG Manavata Cancer Centre
    Nashik, Maharashtra 422001, India
  • Ruby Hall Clinic and Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • Apollo Gleneagles Hospitals Kolkata
    Kolkata, West Bengal 700054, India
  • Max Superspeciality Hospital
    Chandigarh, 160055, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2023, 22 months.

Results were first posted in Nov 2023, 10 months after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 13, 2021
StartActual
Feb 22, 2021
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Results first posted
Nov 21, 2023
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707196
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Feb 22, 2021
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Results posted
Nov 21, 2023
Last update
Nov 24, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion